Document:

EX-10.2

 Exhibit 10.2 

Execution Version 

AMENDMENT NO. 5 TO 

AMENDED AND RESTATED MANAGEMENT AGREEMENT 

THIS AMENDMENT NO. 5 TO AMENDED AND
RESTATED MANAGEMENT AGREEMENT (the “Amendment”), dated as of September 16, 2022, is made pursuant to that certain Amended and Restated Management Agreement dated as of
March 15, 2012, (as amended by the Amendment No. 1 to Amended and Restated Management Agreement, dated as of October 21, 2015, by the Amendment No. 2 to Amended and Restated Management Agreement, dated as of July 24, 2017
(the “Second Amendment”), by the Amendment No. 3 to Amended and Restated Management Agreement, dated as of April 16, 2021 (the “Third Amendment”), by the Amendment No. 4 to Amended and Restated
Management Agreement, dated as of December 30, 2021 (the “Fourth Amendment”) and by the Joinder Agreement, dated as of December 30, 2021, the “Agreement”), among Domino’s Pizza Master Issuer LLC, a
Delaware limited liability company (the “Master Issuer”), Domino’s Pizza Distribution LLC, a Delaware limited liability company (the “Domestic Distributor”), Domino’s SPV Canadian Holding Company Inc., a
Delaware corporation (the “SPV Canadian Holdco”), Domino’s IP Holder LLC, a Delaware limited liability company (the “IP Holder”, and together with the Master Issuer, the Domestic Distributor and SPV Canadian
Holdco, the “Co-Issuers”), Domino’s SPV Guarantor LLC, a Delaware limited liability company (the “SPV Guarantor”), Domino’s Pizza Franchising LLC, a Delaware limited
liability company (the “Domestic Franchisor”), Domino’s Pizza International Franchising Inc., a Delaware corporation (the “International Franchisor”), Domino’s Pizza International Franchising of Michigan
LLC, a Michigan limited liability company (the “International Franchisor (Michigan)”), Domino’s Pizza Canadian Distribution ULC, a Nova Scotia unlimited company (the “Canadian Distributor”), Domino’s EQ
LLC, a Delaware limited liability company (the “Domestic Distribution Equipment Holder”), Domino’s RE LLC, a Delaware limited liability company (the “Domestic Distribution Real Estate Holder”, and together with
the SPV Guarantor, the Domestic Franchisor, the International Franchisor, the International Franchisor (Michigan), the Canadian Distributor and the Domestic Distribution Equipment Holder, the “Guarantors”), Domino’s Pizza LLC,
a Michigan limited liability company (“DPL”), Domino’s Pizza NS Co., a Nova Scotia unlimited company (the “Canadian Manufacturer”), Citibank, N.A. (“Citibank”), as trustee (the
“Trustee”). 
 W I T N E S S
E T H : 
 WHEREAS, Section 8.2 of the Agreement provides, among other
things, that the parties to the Agreement may amend the Agreement from time to time in a writing by such parties; provided that any amendment that could reasonably materially adversely affect the interest of the Noteholders shall require the consent
of the Control Party, which consent shall not be unreasonably withheld; 
 WHEREAS, the
Co-Issuers, the Guarantors, DPL, the Canadian Manufacturer and the Trustee wish to amend the Agreement as set forth herein. 

WHEREAS, the Co-Issuers, the Guarantors, DPL and the Canadian Manufacturer have duly
authorized the execution and delivery of this Amendment; and 
  

 WHEREAS, the Co-Issuers and the
Guarantors have certified to the Trustee pursuant to an Officer’s Certificate that the amendments set forth herein could not reasonably materially adversely affect the interests of the Noteholders; and 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties hereto, intending to be legally bound, agree as follows: 
 Section 1. Defined Terms.
Unless otherwise amended by the terms of this Amendment, terms used in this Amendment shall have the meanings assigned in the Agreement. 

Section 2. Amendment. 

The Agreement is hereby amended to amend and restate the definition of “Weekly Management Fee” appearing in Section 1.1 thereof
in its entirety as follows: 
 “”Weekly Management Fee” means for each Weekly Allocation Date within a Quarterly
Collection Period, either (X) an amount, payable in arrears, determined by dividing (a) the sum (as adjusted pursuant to this definition) of (i) $14,000,000, plus (ii) $4,700 for every integer multiple of $100,000 in
aggregate Retained Collections (excluding PULSE Maintenance Fees and Technology Fees) over the preceding four Quarterly Collection Periods; by (b) 52 or 53, as applicable, based on the number of weeks in the fiscal year; provided, that
the amount in clause (a), as adjusted, shall not exceed an amount equal to 25% of the aggregate amount of Retained Collections (excluding PULSE Maintenance Fees and Technology Fees) with respect to the preceding four Quarterly Collection
Periods or (Y) on and after the Implementation Date (as defined in the Second Amendment), an amount determined by another formula notified by the Master Issuer in writing to the Trustee and the Control Party; provided that (a) the Master
Issuer or the Manager certifies to the Trustee and the Control Party that such other formula was determined in consultation with the Back-Up Manager, (b) after delivering such notification, the Master
Issuer will disclose the then-applicable formula in subsequent Quarterly Noteholders’ Statements and (c) the Master Issuer or the Manager delivers written confirmation to the Trustee and the Control Party that the Rating Agency Condition
with respect to each Series of Notes Outstanding has been satisfied with respect to such new formula. For the avoidance of doubt, the Weekly Management Fee may also be amended in accordance with the amendment provisions in Section 8.21. 
 Section 3. Effectiveness of Amendment. Upon the date hereof (i) the
Agreement shall be amended in accordance herewith, (ii) this Amendment shall form part of the Agreement for all purposes and (iii) the parties and each Noteholder shall be bound by the Agreement, as so amended. Except as expressly set
forth or contemplated in this Amendment, the terms and conditions of the Agreement shall remain in place and shall not be altered, amended or changed in any manner whatsoever, except by any further amendment to the Agreement made in accordance with
the terms of the Agreement, as amended by this Amendment. 
  

	1 	 NTD: Clause (Y) was inserted into the definition of “Weekly Management Agreement” in the Second
Amendment but will only take effect on the date (the “Implementation Date”) that the Series 2015-1 Notes have been paid in full. 

  
 -2- 

 Section 4. Representations and Warranties. Each party hereto represents
and warrants to each other party hereto that this Amendment has been duly and validly executed and delivered by such party and constitutes its legal, valid and binding obligation, enforceable against such party in accordance with its terms. 

Section 5. Binding Effect. This Amendment shall inure to the benefit of and be binding on the respective successors and assigns of
the parties hereto, each Noteholder and each other Secured Party. 
 Section 6. Execution in Counterparts. This Amendment may be
executed in any number of counterparts, each of which so executed shall be deemed to be an original, but all of such counterparts shall together constitute but one and the same instrument. 

Section 7. Governing Law. THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAWS OF THE
STATE OF NEW YORK. 
 Section 8. Trustee. The Trustee assumes no responsibility for the correctness of the recitals contained
herein, which shall be taken as the statements of the Securitization Entities and the Trustee shall not be responsible or accountable in any way whatsoever for or with respect to the validity, execution or sufficiency of this Amendment and makes no
representation with respect thereto. In entering into this Amendment, the Trustee shall be entitled to the benefit of every provision of the Indenture relating to the conduct of or affecting the liability of or affording protection to the Trustee.

 [SIGNATURE PAGES TO FOLLOW] 

 

  
 -3- 

 IN WITNESS WHEREOF, the parties hereto have
caused this Amendment No. 5 to Management Agreement to be executed and delivered by their duly authorized officers as of the date hereof. 
  

			
	DOMINO’S PIZZA LLC, as Manager and in its individual capacity
		
	By:	 	 /s/ Sandeep Reddy

		 	Name: Sandeep Reddy
		 	Title: Chief Financial Officer and Executive Vice President
	
	DOMINO’S PIZZA NS CO.
		
	By:	 	 /s/ Sandeep Reddy

		 	Name: Sandeep Reddy
		 	Title: Chief Financial Officer and Executive Vice President
	
	DOMINO’S PIZZA MASTER ISSUER LLC
		
	By:	 	 /s/ Sandeep Reddy

		 	Name: Sandeep Reddy
		 	Title: Chief Financial Officer and Executive Vice President
	
	DOMINO’S PIZZA DISTRIBUTION LLC
		
	By:	 	 /s/ Sandeep Reddy

		 	Name: Sandeep Reddy
		 	Title: Chief Financial Officer and Executive Vice President

 [Signature Page to Amendment No. 5 to Amended and Restated Management Agreement] 

 
			
	DOMINO’S SPV CANADIAN HOLDING COMPANY INC.
		
	By:	 	 /s/ Sandeep Reddy

		 	Name: Sandeep Reddy
		 	Title: Chief Financial Officer and Executive Vice President
	
	DOMINO’S IP HOLDER LLC
		
	By:	 	 /s/ Sandeep Reddy

	Name: Sandeep Reddy
	Title: Chief Financial Officer and Executive Vice President
	
	DOMINO’S SPV GUARANTOR LLC
		
	By:	 	 /s/ Sandeep Reddy

	Name: Sandeep Reddy
	Title: Chief Financial Officer and Executive Vice President
	
	DOMINO’S PIZZA FRANCHISING LLC
		
	By:	 	 /s/ Sandeep Reddy

	Name: Sandeep Reddy
	Title: Chief Financial Officer and Executive Vice President

 [Signature Page to Amendment No. 5 to Amended and Restated Management Agreement] 

 
			
	DOMINO’S PIZZA INTERNATIONAL FRANCHISING INC.
		
	By:	 	 /s/ Sandeep Reddy

	Name: Sandeep Reddy
	Title: Chief Financial Officer and Executive Vice President

 [Signature Page to Amendment No. 5 to Amended and Restated Management Agreement] 

 
			
	DOMINO’S PIZZA INTERNATIONAL FRANCHISING OF MICHIGAN LLC
		
	By:	 	 /s/ Sandeep Reddy

	Name: Sandeep Reddy
	Title: Chief Financial Officer and Executive Vice President
	
	DOMINO’S PIZZA CANADIAN DISTRIBUTION ULC
		
	By:	 	 /s/ Sandeep Reddy

	Name: Sandeep Reddy
	Title: Chief Financial Officer and Executive Vice President
	
	DOMINO’S EQ LLC
		
	By:	 	 /s/ Sandeep Reddy

	Name: Sandeep Reddy
	Title: Chief Financial Officer and Executive Vice President
	
	DOMINO’S RE LLC
		
	By:	 	 /s/ Sandeep Reddy

	Name: Sandeep Reddy
	Title: Chief Financial Officer and Executive Vice President

 [Signature Page to Amendment No. 5 to Amended and Restated Management Agreement] 

 
			
	CITIBANK, N.A., in its capacity as Trustee
		
	By:	 	 /s/ Jacqueline Suarez

		 	Name: Jacqueline Suarez
		 	Title: Senior Trust Officer

 [Signature Page to Amendment No. 5 to Amended and Restated Management Agreement]Exhibit 4.1

 

THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF,
AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE
WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY
DAYS FOLLOWING [●], 2022 (THE “EFFECTIVE DATE”) TO ANYONE OTHER THAN (I) AEGIS CAPITAL CORP. OR A
SELECTED DEALER IN CONNECTION WITH THE OFFERING FOR WHICH THIS PURCHASE WARRANT WAS ISSUED TO THE UNDERWRITER AS CONSIDERATION (THE “OFFERING”),
OR (II) A BONA FIDE OFFICER OR PARTNER OF AEGIS CAPITAL CORP.

 

THIS PURCHASE WARRANT IS NOT EXERCISABLE PRIOR TO [●]. VOID AFTER
5:00 P.M., EASTERN TIME, [●], 2027.

 

Common
Stock Purchase Warrant

 

For the
Purchase of [●] Shares of Common Stock

 

of

 

Felicitex
Therapeutics Inc.

 

1. Purchase Warrant. THIS CERTIFIES THAT, in consideration
of funds duly paid by or on behalf of Aegis Capital Corp. (“Holder”), as registered owner of this Purchase Warrant
(this “Purchase Warrant”), to Felicitex Therapeutics Inc., a Delaware corporation (the “Company”),
Holder is entitled, at any time or from time to time beginning [●], 2022 (the “Commencement Date”),
and at or before 5:00 p.m., Eastern time, on [●], 2027 (the “Expiration Date”), but not thereafter,
to subscribe for, purchase and receive, in whole or in part, up to [●] shares (the “Warrant Shares”) of
Company common stock, par value $0.0001 per share (the “Common Stock”), subject to adjustment as provided
in Section 6 hereof. If the Expiration Date is not a Business Day, then this Purchase Warrant may be exercised on the next succeeding
Business Day. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase
Warrant. This Purchase Warrant is initially exercisable at $[●] per share of Common Stock; provided, however,
that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the
exercise price per share of Common Stock and the number of shares of Common Stock to be received upon such exercise, shall be adjusted
as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted
exercise price, depending on the context, and the term “Business Day” shall mean a day other than a Saturday,
Sunday or any other day which is a federal legal holiday in the United States or any day on which the Federal Reserve Bank of New York
is authorized or required by law or other governmental action to close, provided that the Federal Reserve Bank of New York shall not be
deemed to be authorized or obligated to be closed due to a “shelter in place,” “non-essential employee” or similar
closure of physical location at the direction of any governmental authority if the bank’s electronic funds transfer systems (including
for wire transfers) are open for use by customers on such day.

 

2. Exercise.

 

2.1 Exercise Form. In order to exercise
this Purchase Warrant, the exercise form attached hereto must be duly executed and completed and delivered to the Company, together with
this Purchase Warrant and, subject to Section 2.2, payment of the Exercise Price for the Common Stock being purchased payable in cash
by wire transfer of immediately available funds to an account designated by the Company or by certified check or official bank check.
If the subscription rights represented hereby shall not be exercised at or before 5:00 p.m., Eastern time, on the Expiration Date, this
Purchase Warrant shall become and be void without further force or effect, and all rights represented hereby shall cease and expire. Each
exercise hereof shall be irrevocable.

 

     

     

    

 

2.2 Cashless Exercise. The Company
shall use its best efforts to cause the Registration Statement to remain effective with a current prospectus and to maintain the registration
of the Common Stock and of the Warrants under the Exchange Act. If at any time on or after the Commencement Date, there is no effective
registration statement registering, or the prospectus contained therein is not available for the issuance of the Purchase Warrant to the
Holder, then this Purchase Warrant may also be exercised, in whole or in part, at such time by means of a “cashless exercise”
in which the Holder shall be entitled to receive the number of Purchase Warrants equal to the quotient obtained by dividing [(A-B) (X)]
by (A), where:

 

		(A)	as applicable: (i) the volume-weighted average price, or “VWAP,” defined below, on the Trading Day immediately preceding
the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof
on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2.1 hereof on a Trading Day prior to the opening
of “regular trading hours” (as defined in Rule 600(b)(77) of Regulation NMS promulgated under the federal securities laws)
on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable
Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time
of the Holder’s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during “regular trading
hours” on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of “regular
trading hours” on a Trading Day) pursuant to Section 2.1 hereof or (iii) the VWAP on the date of the applicable Notice of Exercise
if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section
2.1 hereof after the close of “regular trading hours” on such Trading Day;

 

		(B)	the Exercise Price of this Warrant, as adjusted hereunder; and

 

(X) the number of Warrant Shares that
would be issuable upon exercise of this Purchase Warrant in accordance with the terms of this Warrant if such exercise were by means of
a cash exercise rather than a cashless exercise.

 

If Purchase Warrants are issued in such a “cashless
exercise,” the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall
take on the registered characteristics of the Warrants being exercised, and the holding period of the Warrants being exercised may be
tacked on to the holding period of the Purchase Warrants. The Company agrees not to take any position contrary to this Section 2.2.

 

For purposes of this Section 2.2, the fair market
value of a share of Common Stock is defined as follows:

 

“VWAP” means, for any date, the price determined
by the first of the following clauses that applies: (a) if the Common Stock then listed or quoted on a Trading Market, the daily volume
weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock
are then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New
York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of a share of Common Stock for such
date (or the nearest preceding date) on the OTCQB or OTCQX as applicable, (c) if Common Stock is not then listed or quoted for trading
on the OTCQB or OTCQX and if prices for Common Stock is then reported on the OTC Pink Open Market (or a similar organization or agency
succeeding to its functions of reporting prices), the most recent bid price per Common Stock so reported, or (d) in all other cases, the
fair market value of the Common Stock as determined by an independent appraiser selected in good faith by the Holder and reasonably acceptable
to the Company, the fees and expenses of which shall be paid by the Company.  

 

    2

     

    

 

2.3 Legend. Each certificate for the
securities purchased under this Purchase Warrant shall bear a legend as follows unless such securities have been registered under the
Securities Act of 1933, as amended (the “Act”):

 

The securities represented by this certificate have not
been registered under the Securities Act of 1933, as amended (the “Act”), or applicable state law. Neither the securities
nor any interest therein may be offered for sale, sold or otherwise transferred except pursuant to an effective registration statement
under the Act, or pursuant to an exemption from registration under the Act and applicable state law which, in the opinion of counsel to
Felicitex Therapeutics Inc., is available.

 

2.4 Resale of Shares. Holder and the
Company acknowledge that as of the date hereof the Staff of the Division of Corporation Finance of the SEC has published Compliance &
Disclosure Interpretation 528.04 in the Securities Act Rules section thereof, stating that the holder of securities issued in connection
with a public offering may not rely upon Rule 144 promulgated under the Act to establish an exemption from registration requirements under
Section 4(a)(1) under the Act, but may nonetheless apply Rule 144 constructively for the resale of such shares in the following manner:
(a) provided that six months has elapsed since the last sale under the registration statement, an underwriter or finder may resell the
securities in accordance with the provisions of Rule 144(c), (e), and (f), except for the notice requirement; (b) a purchaser of the shares
from an underwriter receives restricted securities unless the sale is made with an appropriate, current prospectus, or unless the sale
is made pursuant to the conditions contained in (a) above; (c) a purchaser of the shares from an underwriter who receives restricted securities
may include the underwriter’s holding period, provided that the underwriter or finder is not an affiliate of the issuer; and (d)
if an underwriter transfers the shares to its employees, the employees may tack the firm’s holding period for purposes of Rule 144(d),
but they must aggregate sales of the distributed shares with those of other employees, as well as those of the underwriter or finder,
for a six-month period from the date of the transfer to the employees. Holder and the Company also acknowledge that the Staff of the Division
of Corporation Finance of the SEC has advised in various no-action letters that the holding period associated with securities issued without
registration to a service provider commences upon the completion of the services, which the Company agrees and acknowledges shall be the
final closing of the Offering, and that Rule 144(d)(3)(ii) provides that securities acquired from the issuer solely in exchange for other
securities of the same issuer shall be deemed to have been acquired at the same time as the securities surrendered for conversion (which
the Company agrees is the date of the initial issuance of this Purchase Warrant). In the event that following a reasonably-timed written
request by Holder to transfer the shares of Common Stock in accordance with Compliance & Disclosure Interpretation 528.04 counsel
for the Company in good faith concludes that Compliance & Disclosure Interpretation 528.04 no longer may be relied upon as a result
of changes in applicable laws, regulations, or interpretations of the SEC Division of Corporation Finance, or as a result of judicial
interpretations not known by the Company or its counsel on the date hereof (either, a “Registration Trigger Event”),
then the Company shall promptly, and in any event within five (5) Business Days following the request, provide written notice to Holder
of such determination. As a condition to giving such notice, the parties shall negotiate in good faith a single demand registration right
pursuant to an agreement in customary form reasonably acceptable to the parties; provided that notwithstanding anything to the contrary,
the obligations of the Company pursuant to this Section 2 shall terminate on the fifth anniversary of the commencement of sales of the
public offering. In the absence of such conclusion by counsel for the Company, the Company shall, upon such a request of Holder given
no earlier than six months after the final closing of the Offering, instruct its transfer agent to permit the transfer of such shares
in accordance with Compliance & Disclosure Interpretation 528.04, provided that Holder has provided such documentation as shall be
reasonably be requested by the Company to establish compliance with the conditions of Compliance & Disclosure Interpretation 528.04.
Notwithstanding anything to the contrary, pursuant to FINRA Rule 5110(g)(8)(A), the Holder shall not be entitled to more than one demand
registration right hereunder and the duration of the registration rights hereunder shall not exceed five years from the commencement of
sales of the public offering.

   

3. Transfer.

  

3.1 General Restrictions. The registered
Holder of this Purchase Warrant agrees by such Holder’s acceptance hereof, that such Holder will not: (a) sell, transfer, assign,
pledge or hypothecate this Purchase Warrant for a period of one hundred eighty (180) days following the Effective Date to anyone other
than: (i) Holder or an underwriter, placement agent, or a selected dealer participating in the Offering, or (ii) a bona fide officer or
partner of Holder or of any such underwriter, placement agent or selected dealer, in each case in accordance with FINRA Conduct Rule 5110(g)(1),
or (b) for a period of one hundred eighty (180) days following the Effective Date cause this Purchase Warrant or the securities issuable
hereunder to be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic
disposition of this Purchase Warrant or the securities hereunder, except as provided for in FINRA Rule 5110(g)(2). After 180 days after
the Effective Date, transfers to others may be made subject to compliance with or exemptions from applicable securities laws. In order
to make any permitted assignment, the Holder must deliver to the Company the assignment form attached hereto duly executed and completed,
together with the Purchase Warrant and payment of all transfer taxes, if any, payable in connection therewith. The Company shall within
five (5) Business Days transfer this Purchase Warrant on the books of the Company and shall execute and deliver a new Purchase Warrant
or Purchase Warrants of like tenor to the appropriate assignee(s) expressly evidencing the right to purchase the aggregate number of shares
of Common Stock purchasable hereunder or such portion of such number as shall be contemplated by any such assignment.

  

    3

     

    

 

3.2 Restrictions Imposed by the Act.
The securities evidenced by this Purchase Warrant shall not be transferred unless and until: (i) if required by applicable law, the Company
has received the opinion of counsel for the Company that the securities may be transferred pursuant to an exemption from registration
under the Act and applicable state securities laws, or (ii) a registration statement or a post-effective amendment to the registration
statement relating to the offer and sale of such securities has been filed by the Company and declared effective by the U.S. Securities
and Exchange Commission (the “Commission”) and compliance with applicable state securities law has been
established.

 

4. Piggyback Registration Rights.

 

4.1 Grant of Right. In the event that
there is not an effective registration statement covering the Purchase Warrant or the underlying Common Stock, whenever the Company proposes
to register any of its Common Stock under the Act (other than (i) a registration effected solely to implement an employee benefit plan
or a transaction to which Rule 145 of the Act is applicable, or (ii) a registration statement on Form S-4, S-8 or any successor form thereto
or another form not available for registering the Common Stock issuable upon exercise of this Purchase Warrant for sale to the public),
whether for its own account or for the account of one or more stockholders of the Company (a “Piggyback Registration”),
the Company shall give prompt written notice (in any event no later than ten (10) Business Days prior to the filing of such registration
statement) to the Holder of the Company’s intention to effect such a registration and, subject to the remaining provisions of this
Section 4.1, shall include in such registration such number of shares of Common Stock underlying this Purchase Warrant (the “Registrable
Securities”) that the Holder and any other holder of this duly transferred Purchase Warrant pursuant to Section 3 or other
holders of interests in or represented by this Purchase Warrant as otherwise permitted by this Purchase Warrant (collectively, the “Holders”)
have (within ten (10) Business Days of the respective Holder’s receipt of such notice) requested in writing (including such number)
to be included within such registration. If a Piggyback Registration is an underwritten offering and the managing underwriter advises
the Company that it has determined in good faith that marketing factors require a limit on the number of shares of Common Stock to be
included in such registration, including all Common Stock issuable upon exercise of this Purchase Warrant (if the Holder has elected to
include such shares in such Piggyback Registration) and all other Common Stock proposed to be included in such underwritten offering,
the Company shall include in such registration (i) first, the number of shares of Common Stock that the Company proposes to issue and
sell pursuant to such underwritten offering and (ii) second, the number of shares of Common Stock, if any, requested to be included therein
by selling stockholders (including the Holder) allocated pro rata among all such persons on the basis of the number of shares of Common
Stock then owned by each such person. If any Piggyback Registration is initiated as a primary underwritten offering on behalf of the Company,
the Company shall select the investment banking firm or firms to act as the managing underwriter or underwriters in connection with such
offering. Notwithstanding anything to the contrary, the obligations of the Company pursuant to this Section 4.1 shall terminate on the
earlier of (i) the fifth anniversary of the Effective Date and (ii) the date that Rule 144 would allow the Holder to sell its Registrable
Securities during any ninety (90) day period, and shall not be applicable so long as the Company’s Registration Statement on Form
S-1 (No. 333-[__] covering the Registrable Securities remains effective at such time. The duration of the piggyback registration right
shall not exceed seven years from the commencement of sales of the public offering.

  

4.2 Indemnification. The Company shall
indemnify the Holder(s) of the Registrable Securities to be sold pursuant to any registration statement hereunder and each person, if
any, who controls such Holders within the meaning of Section 15 of the Act or Section 20(a) of the Securities Exchange Act of 1934, as
amended (“Exchange Act”), against all loss, claim, damage, expense or liability (including all reasonable attorneys’
fees and other out-of-pocket expenses reasonably incurred in investigating, preparing or defending against any claim whatsoever) to which
any of them may become subject under the Act, the Exchange Act or otherwise, arising from such registration statement but only to the
same extent and with the same effect as the provisions pursuant to which the Company has agreed to indemnify Holder contained in the Underwriting
Agreement between Holder and the Company, dated as of [●], 2022 (the “Underwriting Agreement”). The Holder(s)
of the Registrable Securities to be sold pursuant to such registration statement, and their successors and assigns, shall severally, and
not jointly, indemnify the Company, against all loss, claim, damage, expense or liability (including all reasonable attorneys’ fees
and other expenses reasonably incurred in investigating, preparing or defending against any claim whatsoever) to which they may become
subject under the Act, the Exchange Act or otherwise, arising from information furnished by or on behalf of such Holders, or their successors
or assigns, in writing, for specific inclusion in such registration statement to the same extent and with the same effect as the provisions
contained in the Underwriting Agreement pursuant to which Holder has agreed to indemnify the Company.

 

    4

     

    

 

4.3 Exercise of Purchase Warrants.
Nothing contained in this Purchase Warrant shall be construed as requiring the Holder(s) to exercise their Purchase Warrants prior to
or after the initial filing of any registration statement or the effectiveness thereof.

 

4.4 Documents Delivered to Holders.
The Company shall deliver promptly to each Holder participating in the offering requesting the correspondence and memoranda described
below, copies of all correspondence between the Commission and the Company, its counsel or auditors and all memoranda relating to discussions
with the Commission or its staff with respect to the registration statement and permit each Holder and underwriter to do such investigation,
upon reasonable advance notice, with respect to information contained in or omitted from the registration statement as it deems reasonably
necessary to comply with applicable securities laws or rules of FINRA. Such investigation shall include access to books, records and properties
and opportunities to discuss the business of the Company with its officers and independent auditors, all to such reasonable extent and
at such reasonable times, during normal business hours, as any such Holder shall reasonably request.

 

4.5 Underwriting Agreement. The Holders
shall be parties to any underwriting agreement relating to a Piggyback Registration. Such Holders shall not be required to make any representations
or warranties to or agreements with the Company or the underwriters except as they may relate to such Holders, their Common Stock and
the amount and nature of their ownership thereof and their intended methods of distribution.

 

4.6 Documents to be Delivered by Holder(s).
Each of the Holder(s) participating in any of the foregoing offerings shall furnish to the Company a completed and executed questionnaire
provided by the Company requesting information customarily sought of selling security holders.

  

4.7 Damages. Should the Company fail
to comply with such provisions, the Holder(s) shall, in addition to any other legal or other relief available to the Holder(s), be entitled
to obtain specific performance or other equitable (including injunctive) relief against the threatened breach of such provisions or the
continuation of any such breach, without the necessity of proving actual damages and without the necessity of posting bond or other security.

 

5. New Purchase Warrants to be Issued.

 

5.1 Partial Exercise or Transfer. Subject
to the restrictions in Section 3 hereof, this Purchase Warrant may be exercised or assigned in whole or in part. In the event of the exercise
or assignment hereof in part only, upon surrender of this Purchase Warrant for cancellation, together with the duly executed exercise
or assignment form and funds sufficient to pay any Exercise Price and/or transfer tax if exercised pursuant to Section 2.1 hereto, the
Company shall cause to be delivered to the Holder without charge a new Purchase Warrant of like tenor to this Purchase Warrant in the
name of the Holder evidencing the right of the Holder to purchase the number of Common Stock purchasable hereunder as to which this Purchase
Warrant has not been exercised or assigned.

 

5.2 Lost Certificate. Upon receipt
by the Company of evidence satisfactory to it of the loss, theft, destruction or mutilation of this Purchase Warrant and of reasonably
satisfactory indemnification or the posting of a bond, determined in the sole discretion of the Company, the Company shall execute and
deliver a new Purchase Warrant of like tenor and date. Any such new Purchase Warrant executed and delivered as a result of such loss,
theft, mutilation or destruction shall constitute a substitute contractual obligation on the part of the Company.

 

    5

     

    

 

6. Adjustments.

 

6.1 Adjustments to Exercise Price and Number
of Securities. The Exercise Price and the number of shares of Common Stock underlying the Purchase Warrant shall be subject to adjustment
from time to time as hereinafter set forth:

 

6.1.1 Share Dividends; Split Ups. If,
after the date hereof, and subject to the provisions of Section 6.3 below, the number of outstanding shares of Common Stock is increased
by a stock dividend payable in Common Stock or by a split up of Common Stock or other similar event, then, on the effective day thereof,
the number of shares of Common Stock purchasable hereunder shall be increased in proportion to such increase in outstanding Shares, and
the Exercise Price shall be proportionately decreased.

  

6.1.2 Aggregation of Shares. If, after
the date hereof, and subject to the provisions of Section 6.3 below, the number of outstanding shares of Common Stock is decreased by
a consolidation, combination or reclassification of Common Stock or other similar event, then, on the effective date thereof, the number
of shares of Common Stock purchasable hereunder shall be decreased in proportion to such decrease in outstanding shares of Common Stock,
and the Exercise Price shall be proportionately increased.

 

6.1.3 Replacement of Securities upon Reorganization,
Etc. In case of any reclassification or reorganization of the outstanding Common Stock other than a change covered by Section
6.1.1 or 6.1.2 hereof or that solely affects the par value of such Common Stock, or in the case of any share reconstruction or amalgamation
or consolidation or merger of the Company with or into another corporation (other than a consolidation or share reconstruction or amalgamation
or merger in which the Company is the continuing company and that does not result in any reclassification or reorganization of the outstanding
Common Stock), or in the case of any sale or conveyance to another corporation or entity of the property of the Company as an entirety
or substantially as an entirety in connection with which the Company is dissolved, the Holder of this Purchase Warrant shall have the
right thereafter (until the expiration of the right of exercise of this Purchase Warrant) to receive upon the exercise hereof, for the
same aggregate Exercise Price payable hereunder immediately prior to such event, the kind and amount of shares or other securities or
property (including cash) receivable upon such reclassification, reorganization, share reconstruction or amalgamation, or consolidation,
or upon a dissolution following any such sale or transfer, by a Holder of the number of shares of Common Stock of the Company obtainable
upon exercise of this Purchase Warrant immediately prior to such event; and if any reclassification also results in a change in number
of shares of Common Stock covered by Section 6.1.1 or 6.1.2, then such adjustment shall be made pursuant to Sections 6.1.1, 6.1.2 and
this Section 6.1.3. The provisions of this Section 6.1.3 shall similarly apply to successive reclassifications, reorganizations, share
reconstructions or amalgamations, or consolidations, sales or other transfers.

  

6.1.4 Changes in Form of Purchase Warrant. This
form of Purchase Warrant need not be changed because of any change pursuant to this Section 6.1, and Purchase Warrants issued after such
change may state the same Exercise Price and the same number of shares of Common Stock as are stated in the Purchase Warrants initially
issued pursuant to this Agreement. The acceptance by any Holder of the issuance of new Purchase Warrants reflecting a required or permissive
change shall not be deemed to waive any rights to an adjustment occurring after the Commencement Date or the computation thereof.

 

6.2 Substitute Purchase Warrant. In
case of any consolidation of the Company with, or share reconstruction or amalgamation or merger of the Company with or into, another
corporation (other than a consolidation or share reconstruction or amalgamation or merger which does not result in any reclassification
or change of the outstanding Common Stock), the corporation formed by such consolidation or share reconstruction or amalgamation shall
execute and deliver to the Holder a supplemental Purchase Warrant providing that the holder of each Purchase Warrant then outstanding
or to be outstanding shall have the right thereafter (until the stated expiration of such Purchase Warrant) to receive, upon exercise
of such Purchase Warrant, the kind and amount of shares and other securities and property receivable upon such consolidation or share
reconstruction or amalgamation, by a holder of the number of shares of Common Stock of the Company for which such Purchase Warrant might
have been exercised immediately prior to such consolidation, share reconstruction or amalgamation or merger, sale or transfer. Such supplemental
Purchase Warrant shall provide for adjustments which shall be identical to the adjustments provided for in this Section 6. The above provision
of this Section shall similarly apply to successive consolidations or share reconstructions or amalgamations or mergers.

 

    6

     

    

 

6.3 Elimination of Fractional Interests.
The Company shall not be required to issue certificates representing fractions of shares of Common Stock upon the exercise of the Purchase
Warrant, nor shall it be required to issue scrip or pay cash in lieu of any fractional interests, it being the intent of the parties that
all fractional interests shall be eliminated by rounding any fraction up or down, as the case may be, to the nearest whole number of shares
of Common Stock or other securities, properties or rights.

 

7.  Reservation. The Company shall at all times reserve
and keep available out of its authorized Common Stock, solely for the purpose of issuance upon exercise of the Purchase Warrants, such
number of shares of Common Stock or other securities, properties or rights as shall be issuable upon the exercise thereof. The Company
covenants and agrees that, upon exercise of the Purchase Warrants and payment of the Exercise Price therefor, in accordance with the terms
hereby, all Common Stock and other securities issuable upon such exercise shall be duly and validly issued, fully paid and non-assessable
and not subject to preemptive rights of any shareholder.

  

8. Certain Notice Requirements.

 

8.1 Holder’s Right to Receive Notice.
Nothing herein shall be construed as conferring upon the Holder the right to vote or consent or to receive notice as a shareholder for
the election of directors or any other matter, or as having any rights whatsoever as a shareholder of the Company. If, however, at any
time prior to the expiration of the Purchase Warrants and their exercise, any of the events described in Section 8.2 shall occur, then,
in one or more of said events, the Company shall deliver to each Holder a copy of each notice relating to such events given to the other
shareholders of the Company at the same time and in the same manner that such notice is given to the shareholders.

 

8.2 Events Requiring Notice. The Company
shall be required to give the notice described in this Section 8 upon one or more of the following events: (i) if the Company shall take
a record of the holders of its Common Stock for the purpose of entitling them to receive a dividend or distribution payable otherwise
than in cash, or a cash dividend or distribution payable otherwise than out of retained earnings, as indicated by the accounting treatment
of such dividend or distribution on the books of the Company, or (ii) the Company shall offer to all the holders of its Common Stock any
additional shares of capital stock of the Company or securities convertible into or exchangeable for shares of capital stock of the Company,
or any option, right or warrant to subscribe therefor.

 

8.3 Notice of Change in Exercise Price.
The Company shall, within three (3) Business Days after an event requiring a change in the Exercise Price pursuant to Section 6 hereof,
send notice to the Holders of such event and change (“Price Notice”). The Price Notice shall describe the event
causing the change and the method of calculating same.

 

8.4 Transmittal of Notices. All notices,
requests, consents and other communications under this Purchase Warrant shall be in writing and delivered personally, by e-mail, or sent
by a nationally recognized overnight courier service to following addresses or to such other address as the Holder or the Company may
designate by notice to the other party and shall be deemed given and effective on the earliest of (i) the time of transmission, if such
notice or communication is delivered via e-mail (with confirmation of receipt from the intended recipient by return e-mail or other written
acknowledgment) at the e-mail address set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Business
Day after the time of transmission, if such notice or communication is delivered via e-mail (with confirmation of receipt from the intended
recipient by return email or other written acknowledgment) at the e-mail address set forth in this Section on a day that is not a Business
Day or later than 5:30 p.m. (New York City time) on any Business Day, (iii) the second Business Day following the date of mailing, if
sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required
to be given:

 

    7

     

    

 

If to the Holder:

 

Aegis Capital Corp.,

810 Seventh Avenue, 18th Floor,

New York, NY 10019,

Attention: Global Equity Markets

E-mail: [●]

 

with a copy (which shall not constitute notice) to:

 

Matthew W. Mamak

Alston & Bird LLP

90 Park Avenue, Floor 14

New York, NY 10016

E-mail: matthew.mamak@alston.com

 

If to the Company:

 

Felicitex Therapeutics Inc.

27 Strathmore Road

Natick, MA 01760

Attention: Maria Vilenchik, Chief Executive Officer

E-mail: mvilenchik@felicitex.com

 

with a copy (which shall not constitute notice) to:

 

Louis Bevilacqua

Bevilacqua PLLC

1050 Connecticut Avenue, NW, Suite 500

Washington, DC 20036

Email: lou@bevilacquapllc.com

 

9. Miscellaneous.

 

9.1 Amendments. The Company and Holder
may from time to time supplement or amend this Purchase Warrant without the approval of any of the Holders in order to cure any ambiguity,
to correct or supplement any provision contained herein that may be defective or inconsistent with any other provisions herein, or to
make any other provisions in regard to matters or questions arising hereunder that the Company and Holder may deem necessary or desirable
and that the Company and Holder deem shall not adversely affect the interest of the Holders. All other modifications or amendments shall
require the written consent of and be signed by (i) the Company and (ii) the Holder(s) of Purchase Warrants then-exercisable for at least
a majority of the Common Stock then-exercisable pursuant to all then-outstanding Purchase Warrants.

 

9.2 Headings. The headings contained
herein are for the sole purpose of convenience of reference, and shall not in any way limit or affect the meaning or interpretation of
any of the terms or provisions of this Purchase Warrant.

 

9.3 Entire Agreement. This Purchase
Warrant (together with the other agreements and documents being delivered pursuant to or in connection with this Purchase Warrant) constitutes
the entire agreement of the parties hereto with respect to the subject matter hereof, and supersedes all prior agreements and understandings
of the parties, oral and written, with respect to the subject matter hereof.

 

9.4 Binding Effect. This Purchase Warrant
shall inure solely to the benefit of and shall be binding upon, the Holder and the Company and their permitted assignees, respective successors,
legal representative and assigns, and no other person shall have or be construed to have any legal or equitable right, remedy or claim
under or in respect of or by virtue of this Purchase Warrant or any provisions herein contained.

 

    8

     

    

 

9.5 Governing Law; Submission to Jurisdiction;
Trial by Jury. This Purchase Warrant shall be governed by and construed and enforced in accordance with the laws of the State of New
York, without giving effect to conflict of laws principles thereof. The Company hereby agrees that any action, proceeding or claim against
it arising out of, or relating in any way to this Purchase Warrant shall be brought and enforced in the courts located in the City of
New York, County of New York, and State of New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive.
The Company hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum. Any process
or summons to be served upon the Company may be served by transmitting a copy thereof by registered or certified mail, return receipt
requested, postage prepaid, addressed to it at the address set forth in Section 8 hereof. Such mailing shall be deemed personal service
and shall be legal and binding upon the Company in any action, proceeding or claim. The Company and the Holder agree that the prevailing
party(ies) in any such action shall be entitled to recover from the other party(ies) all of its reasonable attorneys’ fees and expenses
relating to such action or proceeding and/or incurred in connection with the preparation therefor. The Company (on its behalf and, to
the extent permitted by applicable law, on behalf of its stockholders and affiliates) and the Holder hereby irrevocably waive, to the
fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this
Agreement or the transactions contemplated hereby.

 

9.6 Non-Waiver. The failure of the
Company or the Holder to at any time enforce any of the provisions of this Purchase Warrant shall not be deemed or construed to be a waiver
of any such provision, nor to in any way affect the validity of this Purchase Warrant or any provision hereof or the right of the Company
or any Holder to thereafter enforce each and every provision of this Purchase Warrant. No waiver of any breach, non-compliance or non-fulfillment
of any of the provisions of this Purchase Warrant shall be effective unless set forth in a written instrument executed by the party or
parties against whom or which enforcement of such waiver is sought; and no waiver of any such breach, non-compliance or non-fulfillment
shall be construed or deemed to be a waiver of any other or subsequent breach, non-compliance or non-fulfillment.

 

9.7 Exchange Agreement. As a condition
of the Holder’s receipt and acceptance of this Purchase Warrant, Holder agrees that, at any time prior to the complete exercise
of this Purchase Warrant by Holder, if the Company and Holder enter into an agreement (“Exchange Agreement”)
pursuant to which they agree that all outstanding Purchase Warrants will be exchanged for securities or cash or a combination of both,
then Holder shall agree to such exchange and become a party to the Exchange Agreement.

 

10. Certain Definitions. As used herein, the following terms
shall have the following meanings:

 

10.1 “Bid Price” means, for
any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on
a Trading Market, the bid price of a share of Common Stock for the time in question (or the nearest preceding date) on the Trading Market
on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City
time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average per share price of
the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed
or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock is then reported on the Pink Open Market (or a similar organization
or agency succeeding to its functions of reporting prices), the most recent bid price per share of Common Stock so reported, or (d) in
all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by
the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses
of which shall be paid by the Company.

 

10.2 “Notice of Exercise” means
the form attached hereto as Exhibit A.

 

10.3 “Offering” means the Company’s
initial public offering.

 

10.4 “Trading Day” means a day
on which the Common Stock is traded on a Trading Market.

 

10.5 “Trading Market” means
any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE
American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, OTCQB or
OTCQX (or any successors to any of the foregoing).

 

[Signature Page Follows]

 

    9

     

    

 

IN WITNESS WHEREOF, the Company has caused this
Purchase Warrant to be signed by its duly authorized officer as of the date first written above.

 

	Felicitex Therapeutics Inc.	 
	 	 
	By:	 	 
	 	Name: 	Maria Vilenchik	 
	 	Title:	Chief Executive Officer	 

 

    10

     

    

 

Exhibit A 

 

Notice of Exercise

 

[Form to be used to exercise Purchase Warrant]

 

Date: __________, 20___

 

The undersigned hereby elects irrevocably to exercise
the Purchase Warrant for ______ shares of common stock, par value $0.0001 per share (the “Common Stock”),
of Felicitex Therapeutics Inc., a Delaware corporation (the “Company”), and hereby makes payment of $____
(at the rate of $____ per share of Common Stock) in payment of the Exercise Price pursuant thereto. Please issue the Common Stock as to
which this Purchase Warrant is exercised in accordance with the instructions given below and, if applicable, a new Purchase Warrant representing
the number of shares of Common Stock for which this Purchase Warrant has not been exercised.

 

or

 

The undersigned hereby elects
irrevocably to convert its right to purchase ______ shares of Common Stock under the Purchase Warrant for ______ shares of Common Stock,
as determined in accordance with the formula set forth in Section 2.2 of the Purchase Warrant.

 

 

Please issue the Common Stock as to which this
Purchase Warrant is exercised in accordance with the instructions given below and, if applicable, a new Purchase Warrant representing
the number of shares of Common Stock for which this Purchase Warrant has not been converted.

 

Signature                                                                               

 

Signature Guaranteed                                                              

  

INSTRUCTIONS FOR REGISTRATION OF SECURITIES

 

Name:                                                                                  

(Print in Block Letters)

 

Address:                                                                
           

                  
                                                             
             

 

NOTICE: The signature to this form must correspond
with the name as written upon the face of the Purchase Warrant without alteration or enlargement or any change whatsoever, and must be
guaranteed by a bank, other than a savings bank, or by a trust company or by a firm having membership on a registered national securities
exchange.

 

    11

     

    

 

Exhibit B

 

[Form to be used to assign Purchase Warrant]

 

ASSIGNMENT

 

(To be executed by the registered Holder to effect
a transfer of the within Purchase Warrant):

 

FOR VALUE RECEIVED, __________________ does hereby sell, assign and
transfer unto the right to purchase common stock, par value $0.0001 per share, of Felicitex Therapeutics Inc., a Delaware corporation
(the “Company”), evidenced by the Purchase Warrant and does hereby authorize the Company to transfer such
right on the books of the Company.

 

Dated: __________, 20__

 

Signature                                                                      

 

Signature Guaranteed                                                 

  

NOTICE: The signature to this form must correspond with the name as
written upon the face of the within Purchase Warrant without alteration or enlargement or any change whatsoever, and must be guaranteed
by a bank, other than a savings bank, or by a trust company or by a firm having membership on a registered national securities exchange.

 

 

12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}]]